Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07301268) titled 'GI-102 Alone or in Combination With Pembrolizumab Before Surgery for the Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma' on Dec. 22, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Mayo Clinic
Condition:
Glioblastoma, IDH-Wildtype
Progressive Astrocytoma, IDH-Mutant, Grade 4
Progressive Glioblastoma
Progressive Gliosarcoma
Recurrent Astrocytoma, IDH-Mutant, Grade 4
Recurrent Glioblastoma, IDH-Wildtype
Recurrent Gliosarcoma
Res...